Homology modeling of transporter proteins (carriers and ion channels).

Transporter proteins are divided into channels and carriers and constitute families of membrane proteins of physiological and pharmacological importance. These proteins are targeted by several currently prescribed drugs, and they have a large potential as targets for new drug development. Ion channels and carriers are difficult to express and purify in amounts for X-ray crystallography and nuclear magnetic resonance (NMR) studies, and few carrier and ion channel structures are deposited in the PDB database. The scarcity of atomic resolution 3D structures of carriers and channels is a problem for understanding their molecular mechanisms of action and for designing new compounds with therapeutic potentials. The homology modeling approach is a valuable approach for obtaining structural information about carriers and ion channels when no crystal structure of the protein of interest is available. In this chapter, computational approaches for constructing homology models of carriers and transporters are reviewed.

[1]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[2]  S Kitayama,et al.  Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Levitt.  Accurate modeling of protein conformation by automatic segment matching. , 1992, Journal of molecular biology.

[4]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[5]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[6]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[7]  D. Keppler,et al.  ATP‐dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P‐glycoprotein , 1994, FEBS letters.

[8]  C. Sander,et al.  Errors in protein structures , 1996, Nature.

[9]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[10]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[11]  G. Rudnick,et al.  The Third Transmembrane Domain of the Serotonin Transporter Contains Residues Associated with Substrate and Cocaine Binding* , 1997, The Journal of Biological Chemistry.

[12]  H. Mewes,et al.  Protein structural classes in five complete genomes , 1997, Nature Structural Biology.

[13]  H. Kaback,et al.  From membrane to molecule to the third amino acid from the left with a membrane transport protein , 1997, Quarterly Reviews of Biophysics.

[14]  G. Heijne,et al.  Genome‐wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms , 1998, Protein science : a publication of the Protein Society.

[15]  D. Meijer,et al.  Interactions between P‐glycoprotein substrates and other cationic drugs at the hepatic excretory level , 1998, British journal of pharmacology.

[16]  Sean R. Eddy,et al.  Profile hidden Markov models , 1998, Bioinform..

[17]  Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. , 1999, Anticancer research.

[18]  M. Saier.  A Functional-Phylogenetic Classification System for Transmembrane Solute Transporters , 2000, Microbiology and Molecular Biology Reviews.

[19]  B. S. Park,et al.  Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter. , 2000, Molecular pharmacology.

[20]  K. Linton,et al.  The xyz of ABC Transporters , 2001, Science.

[21]  E. Wang,et al.  Interaction of Common Azole Antifungals with P Glycoprotein , 2002, Antimicrobial Agents and Chemotherapy.

[22]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[23]  D. Clarke,et al.  Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.

[24]  D. Clarke,et al.  Methanethiosulfonate Derivatives of Rhodamine and Verapamil Activate Human P-glycoprotein at Different Sites* , 2003, Journal of Biological Chemistry.

[25]  J. Sear.  Pharmacology, 5th Edn , 2003 .

[26]  Martin Caffrey,et al.  Membrane protein crystallization. , 2003, Journal of structural biology.

[27]  S. Iwata,et al.  Structure and Mechanism of the Lactose Permease of Escherichia coli , 2003, Science.

[28]  Finn Drabløs,et al.  Homology-based modelling of targets for rational drug design. , 2004, Mini reviews in medicinal chemistry.

[29]  Avinash Peddi,et al.  Electronic Reprint Biological Crystallography a Robotic System for Crystallizing Membrane and Soluble Proteins in Lipidic Mesophases Biological Crystallography a Robotic System for Crystallizing Membrane and Soluble Proteins in Lipidic Mesophases , 2022 .

[30]  Ceslovas Venclovas,et al.  Progress over the first decade of CASP experiments , 2005, Proteins.

[31]  P. Bradley,et al.  Toward High-Resolution de Novo Structure Prediction for Small Proteins , 2005, Science.

[32]  Lutz Schmitt,et al.  The motor domains of ABC-transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[33]  D. Clarke,et al.  Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux , 2005, The Journal of Membrane Biology.

[34]  P. Borst,et al.  Multidrug resistance-associated proteins 3, 4, and 5 , 2007, Pflügers Archiv - European Journal of Physiology.

[35]  D. Clarke,et al.  Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. , 2006, The Biochemical journal.

[36]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[37]  D. Clarke,et al.  Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. , 2006, The Biochemical journal.

[38]  B. Honig,et al.  On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins. , 2006, Biophysical journal.

[39]  Harel Weinstein,et al.  A Comprehensive Structure-Based Alignment of Prokaryotic and Eukaryotic Neurotransmitter/Na+ Symporters (NSS) Aids in the Use of the LeuT Structure to Probe NSS Structure and Function , 2006, Molecular Pharmacology.

[40]  V. Cherezov,et al.  Room to move: crystallizing membrane proteins in swollen lipidic mesophases. , 2006, Journal of molecular biology.

[41]  Multidrug ABC transporter SAV1866 , 2006 .

[42]  Geoffrey Chang,et al.  Flexibility in the ABC transporter MsbA: Alternating access with a twist , 2007, Proceedings of the National Academy of Sciences.

[43]  A. Ravna,et al.  Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5) , 2007, Theoretical Biology & Medical Modelling.

[44]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[45]  Da-Neng Wang,et al.  LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake , 2007, Science.

[46]  R. Casadio,et al.  Thinking the impossible: how to solve the protein folding problem with and without homologous structures and more. , 2007, Methods in molecular biology.

[47]  Eric Gouaux,et al.  Antidepressant binding site in a bacterial homologue of neurotransmitter transporters , 2007, Nature.

[48]  A. Ravna,et al.  A molecular model of a putative substrate releasing conformation of multidrug resistance protein 5 (MRP5). , 2008, European journal of medicinal chemistry.

[49]  A. Ravna,et al.  Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). , 2008, Bioorganic & medicinal chemistry letters.

[50]  J. Gies,et al.  Drugs and their molecular targets: an updated overview , 2008, Fundamental & clinical pharmacology.

[51]  Kaihsu Tai,et al.  Molecular modeling and simulation studies of ion channel structures, dynamics and mechanisms. , 2008, Methods in cell biology.

[52]  P. Taylor,et al.  Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal α7 nicotinic acetylcholine receptor , 2009, The EMBO journal.

[53]  R. Sakai,et al.  Full Domain Closure of the Ligand-binding Core of the Ionotropic Glutamate Receptor iGluR5 Induced by the High Affinity Agonist Dysiherbaine and the Functional Antagonist 8,9-Dideoxyneodysiherbaine* , 2009, Journal of Biological Chemistry.

[54]  Ingebrigt Sylte,et al.  Structure and localisation of drug binding sites on neurotransmitter transporters , 2009, Journal of molecular modeling.

[55]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[56]  Ingebrigt Sylte,et al.  Theoretical Biology and Medical Modelling Open Access Binding Site of Abc Transporter Homology Models Confirmed by Abcb1 Crystal Structure , 2022 .

[57]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.